How fast does CJC-1295 / ipamorelin start working?

The growth-hormone pulse itself is fast — mean GH rises within about an hour of a subcutaneous dose, and in the foundational CJC-1295 human study a single injection produced a 2–10 fold GH increase. But that pulse is a biochemical event, not a felt effect. The downstream results are mediated by IGF-1, which builds over days to weeks, so the practical answer is measured in weeks, not hours. These are published research figures, not medical advice.

How long until IGF-1 and the downstream effects build?

In the Teichman 2006 study, a single CJC-1295 injection raised IGF-1 by 1.5–3 fold and kept it elevated for up to two weeks. With the no-DAC short-acting blend, keeping IGF-1 sustained takes repeated pulses, so the meaningful timeline is the accumulation of dosing across weeks. The reported experience places recovery and body-composition changes roughly in the four-to-twelve-week window as IGF-1 stays elevated.

Why don't I 'feel' anything right after a dose?

Because the fast clock (the GH pulse) and the slow clock (IGF-1-mediated tissue effects) are different. The GH pulse is measurable on an assay but has a very short residence time, and growth hormone works largely by driving IGF-1 production. The effects people track — recovery, body composition, connective-tissue and skin changes — follow the IGF-1 build, which lags the injection by days to weeks.

Is there a human trial that pins down the exact timeline?

Not for the specific combination. The pharmacodynamic timing comes from the individual-component research, chiefly the CJC-1295 healthy-adult study; no validated human trial of the CJC-1295 + ipamorelin blend has been published. That is why the week-band descriptions on this page are qualitative ranges reproduced as a research reference rather than a guaranteed schedule.

Is CJC-1295 / ipamorelin approved for human use?

No. The blend is not an approved therapeutic and has no combination-specific human trial. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic or preventative use. The time-course information here summarises published research and is not medical or dosing advice.

CJC-1295 + ipamorelin · time-to-effect · research use only

How long does CJC-1295 / ipamorelin take to work? The two-clock answer.

This is a two-clock question, and conflating the clocks is where most answers go wrong. The first clock is immediate: the peptides trigger a growth-hormone pulse within roughly an hour of a subcutaneous dose — that is a measurable event, not a felt one. The second clock is slower: growth hormone drives the liver to produce IGF-1, and it is IGF-1 — not the GH pulse itself — that mediates the downstream tissue effects, building over days to weeks. The single most-cited human study of CJC-1295 (Teichman et al., JCEM 2006) captured exactly this: one injection produced a 2–10 fold rise in mean GH sustained for about six days, and a 1.5–3 fold rise in IGF-1 that stayed elevated for up to two weeks. This page reproduces that trajectory as a research reference — the acute pulse, the IGF-1 build, and why the things people actually track (recovery, body composition, sleep) sit weeks out from the first dose. It is a summary of published research, not a human-use protocol or medical advice.

CJC-1295 + Ipamorelin blend — $119.99 CJC-1295 / ipamorelin dosage

The GH pulse is immediate — within about an hour

Growth-hormone release is the fast clock. Ipamorelin initiates a GH pulse and CJC-1295 amplifies and extends it, so mean GH rises within roughly an hour of a subcutaneous dose. In the foundational human CJC-1295 study a single injection produced a 2–10 fold increase in mean GH concentration over baseline. But GH itself has a very short residence time, and this pulse is a biochemical event you would measure on an assay, not an effect you would feel. It is the trigger, not the outcome.

The half-life detail →

IGF-1 is the slow clock — it builds over days to two weeks

The effects people care about are mediated by IGF-1, which the liver produces in response to the GH pulse. In the Teichman study a single CJC-1295 injection raised IGF-1 by 1.5–3 fold and kept it elevated for up to two weeks. With the no-DAC short-acting form Titan supplies, repeated pulses are needed to keep IGF-1 sustained — so the meaningful timeline is the accumulation of daily pulses across weeks, not any single shot. This is why 'how long does it take' is answered in weeks, not hours.

What to expect early →

Weeks 1–4: the earliest reported changes

In the reported experience the first month is dominated by the acute signals of a rising GH axis rather than the payoff: transient water retention as sodium balance shifts, sometimes deeper or improved sleep in the early weeks, and the injection-site and flushing effects that also front-load here. Body-composition change is generally not yet apparent. Framing the first four weeks as an adaptation window, not a results window, matches the kinetics.

Dosing cadence →

Weeks 4–12: where the downstream effects consolidate

The reported timeline places the more sought-after changes — recovery, body-composition shifts, connective-tissue and skin effects tied to collagen synthesis — in the roughly four-to-twelve-week window, as sustained IGF-1 elevation does its work and the early water-retention effect settles. This is consistent with IGF-1 being a builder hormone: the tissue-level outcomes lag the hormonal signal by weeks. There is no validated human combination trial putting exact dates on these, so they are described as ranges, not guarantees.

How it compares to sermorelin →

Beyond 12 weeks: the timeline becomes a monitoring question

Past the first few months the relevant 'timeline' stops being about onset and becomes about staying in a physiologic range. Longer research protocols model periodic IGF-1 checks to confirm the level has not drifted chronically above the age-adjusted range, because sustained supraphysiologic GH/IGF-1 is where joint and insulin-sensitivity concerns appear. The compound keeps working on the same two clocks; the variable that matters shifts from 'is it working yet' to 'is it staying in range'.

DAC vs no-DAC kinetics →

Research-use framing

Every figure here comes from the published peptide literature — principally the CJC-1295 healthy-adult pharmacodynamic study — and is reproduced as a research reference for laboratory and in-vitro modelling, not as a prediction of any individual's timeline and not as instructions for human use. No validated human trial of the specific CJC-1295 + ipamorelin combination exists. Titan supplies the blend strictly as a research-use-only reagent, not for human or animal consumption. Nothing here is medical advice.

Lab testing & COA workflow →

The detail, in plain terms

The time-course, at a glance.

Reference points drawn from the published CJC-1295 human pharmacodynamic data (Teichman et al., JCEM 2006, n=65) plus the reported component experience, reproduced as a research reference. The week-band descriptions are qualitative ranges, not a validated human combination schedule, because no combination-specific trial exists.

GH pulse onset: Within ~1 hour of a subcutaneous dose; mean GH rose 2–10 fold in the CJC-1295 human study.
GH elevation duration: Sustained ~6 days after a single CJC-1295 injection in the foundational study.
IGF-1 response: Rose 1.5–3 fold and stayed elevated up to ~2 weeks after a single injection.
No-DAC form (Titan blend): Short-acting pulses; sustained IGF-1 requires repeated dosing, so the meaningful clock is weeks of accumulated pulses.
Weeks 1–4: Adaptation window — water retention, early sleep changes, acute injection effects; body-comp change not yet apparent.
Weeks 4–12: Where recovery, body-composition and collagen-linked effects are reported to consolidate as IGF-1 stays elevated.
Beyond 12 weeks: Timeline becomes a monitoring question — periodic IGF-1 checks to stay within the age-adjusted range.
Human combination trial: None published; the timeline is built from component data, so all figures are references, not guarantees.

Questions researchers ask

Before you order.

How fast does CJC-1295 / ipamorelin start working?: The growth-hormone pulse itself is fast — mean GH rises within about an hour of a subcutaneous dose, and in the foundational CJC-1295 human study a single injection produced a 2–10 fold GH increase. But that pulse is a biochemical event, not a felt effect. The downstream results are mediated by IGF-1, which builds over days to weeks, so the practical answer is measured in weeks, not hours. These are published research figures, not medical advice.
How long until IGF-1 and the downstream effects build?: In the Teichman 2006 study, a single CJC-1295 injection raised IGF-1 by 1.5–3 fold and kept it elevated for up to two weeks. With the no-DAC short-acting blend, keeping IGF-1 sustained takes repeated pulses, so the meaningful timeline is the accumulation of dosing across weeks. The reported experience places recovery and body-composition changes roughly in the four-to-twelve-week window as IGF-1 stays elevated.
Why don't I 'feel' anything right after a dose?: Because the fast clock (the GH pulse) and the slow clock (IGF-1-mediated tissue effects) are different. The GH pulse is measurable on an assay but has a very short residence time, and growth hormone works largely by driving IGF-1 production. The effects people track — recovery, body composition, connective-tissue and skin changes — follow the IGF-1 build, which lags the injection by days to weeks.
Is there a human trial that pins down the exact timeline?: Not for the specific combination. The pharmacodynamic timing comes from the individual-component research, chiefly the CJC-1295 healthy-adult study; no validated human trial of the CJC-1295 + ipamorelin blend has been published. That is why the week-band descriptions on this page are qualitative ranges reproduced as a research reference rather than a guaranteed schedule.
Is CJC-1295 / ipamorelin approved for human use?: No. The blend is not an approved therapeutic and has no combination-specific human trial. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic or preventative use. The time-course information here summarises published research and is not medical or dosing advice.